Phase 3 results position telitacicept as potential best-in-disease profile in primary Sjögren's disease Telitacicept ...

While Vor provided no details on the results, the company is now evaluating a global trial of the drug in the chronic immune ...

Yantai-based RemeGen said it will now move ahead with filing telitacicept with China's National Medical Products ...

The China-based phase 3 trial of telitacicept in primary Sjögren's syndrome (pSS) met its primary endpoint, which focused on ...

Novartis may have abandoned one Sjögren's syndrome asset this year, but it looks like the drugmaker has a winner on its hands ...

Vor Bio (VOR) announced on Wednesday that its collaborator, RemeGen Co., achieved the primary goal in a late-stage study in ...

On August 13th, Remegen (688331.SH/09995.HK) announced that its global first-in-class BLyS (BAFF)/APRIL dual-target fusion ...

Vor Bio shares climb as RemeGen's Phase 3 study in China shows telitacicept improves disease activity in primary Sjögren's ...

The drug, ianalumab, met its objectives in two Phase 3 studies in Sjögren’s syndrome, boosting the outlook of a ...

A day after posting a pair of phase 3 wins for the tricky indication of Sjögren's syndrome, the Swiss pharma has unveiled a ...

Ianalumab is a fully human monoclonal antibody designed to deplete B cells via antibody-dependent cellular toxicity and inhibit BAFF-R-mediated signals of B cell function and survival.